AAAAAA
Results:
1-22
|
Results: 22
Authors:
Campos, H
Moye, LA
Glasser, SP
Stampfer, MJ
Sacks, FM
Citation: H. Campos et al., Low-density lipoprotein size, pravastatin treatment, and coronary events, J AM MED A, 286(12), 2001, pp. 1468-1474
Authors:
Morgenstern, LB
Steffen-Batey, L
Smith, MA
Moye, LA
Citation: Lb. Morgenstern et al., Barriers to acute stroke therapy and stroke prevention in Mexican Americans, STROKE, 32(6), 2001, pp. 1360-1364
Authors:
Moye, LA
Citation: La. Moye, Random research, CIRCULATION, 103(25), 2001, pp. 3150-3153
Authors:
Bray, PF
Cannon, CP
Goldschmidt-Clermont, P
Moye, LA
Pfeffer, MA
Sacks, FM
Braunwald, E
Citation: Pf. Bray et al., The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction, AM J CARD, 88(4), 2001, pp. 347-352
Authors:
Moye, LA
Pfeffer, MA
Citation: La. Moye et Ma. Pfeffer, Attenuation of ventricular enlargement: The SAVE study, CLINICAL TRIALS IN HYPERTENSION, 2001, pp. 469-498
Authors:
Moye, LA
Annegers, AF
Citation: La. Moye et Af. Annegers, Underestimation of the valvulopathy effect of fenfluramine, J AM COL C, 36(4), 2000, pp. 1434-1435
Authors:
Moye, LA
Citation: La. Moye, Alpha calculus in clinical trials: considerations and commentary for the new millennium, STAT MED, 19(6), 2000, pp. 767-779
Authors:
Moye, LA
Citation: La. Moye, Response to commentaries on 'Alpha calculus in clinical trials: considerations for the new millennium', STAT MED, 19(6), 2000, pp. 795-799
Authors:
Bornschein, RL
Chisolm, JJ
Damokosh, AI
Dockery, DW
Fay, ME
Jones, RL
Rhoads, GG
Ragan, NB
Rogan, WJ
Salganik, M
Schwarz, DF
Ware, JH
Wedeen, RP
Serwint, J
Brophy, M
Davoli, CT
Denckla, MB
Farfel, MR
Goldstein, GW
Rubin, J
Berger, O
Dietrich, KN
Wesolowski, C
Wilkins, S
Maynard-Wentzel, G
Mortensen, ME
Adubato, S
El-safty, M
Heenehan, M
Sheffet, A
Ty, A
Campbell, C
Gill, FM
Guinn, J
Henretig, F
Knight, D
Radcliffe, J
Schwarz, DF
Bowman, BB
Gunter, E
Huff, D
Jones, RL
Miller, DT
Paschal, DC
Bernstein, AJ
Kotlov, TV
Salganik, M
Angle, CR
Faison, J
Gehlbach, SH
Gray-Little, B
James, SA
Moye, LA
Needleman, HL
Citation: Rl. Bornschein et al., Safety and efficacy of succimer in toddlers with blood lead levels of 20-44 mu g/dL, PEDIAT RES, 48(5), 2000, pp. 593-599
Authors:
Morgenstern, LB
Wein, TH
Smith, MA
Moye, LA
Pandey, DK
Labarthe, DR
Citation: Lb. Morgenstern et al., Comparison of stroke hospitalization rates among Mexican-Americans and non-Hispanic whites, NEUROLOGY, 54(10), 2000, pp. 2000-2002
Authors:
Sacks, FM
Alaupovic, P
Moye, LA
Cole, TG
Sussex, B
Stampfer, MJ
Pfeffer, MA
Braunwald, E
Citation: Fm. Sacks et al., VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial, CIRCULATION, 102(16), 2000, pp. 1886-1892
Authors:
Sacks, FM
Pfeffer, MA
Moye, LA
Hawkins, CM
Davis, BR
Rouleau, JL
Cole, TG
Braunwald, E
Citation: Fm. Sacks et al., Cholesterol and recurrent events trial (CARE) - The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, CHOLESTEROL-LOWERING THERAPY, 2000, pp. 63-89
Authors:
Richardson, MA
Ramirez, T
Russell, NC
Moye, LA
Citation: Ma. Richardson et al., Coley toxins immunotherapy: A retrospective review, ALTERN TH H, 5(3), 1999, pp. 42-47
Authors:
Flaker, GC
Warnica, JW
Sacks, FM
Moye, LA
Davis, BR
Rouleau, JL
Webel, RR
Pfeffer, MA
Braunwald, E
Citation: Gc. Flaker et al., Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations, J AM COL C, 34(1), 1999, pp. 106-112
Authors:
Pfeffer, MA
Sacks, FM
Moye, LA
East, C
Goldman, S
Nash, DT
Rouleau, JR
Rouleau, JL
Sussex, BA
Theroux, P
Citation: Ma. Pfeffer et al., Influence of baseline lipids on effectiveness of pravastatin in the CARE trial, J AM COL C, 33(1), 1999, pp. 125-130
Authors:
Mikhail, O
Swint, JM
Brinker, MR
Moye, LA
Sabino, M
Citation: O. Mikhail et al., Technology evolution - The technology spectrum and its application to orthopedic technologies, INT J TE A, 15(1), 1999, pp. 254-263
Authors:
Fisher, LD
Moye, LA
Citation: Ld. Fisher et La. Moye, Carvedilol and the Food and Drug Administration approval process: An introduction, CONTR CL TR, 20(1), 1999, pp. 1-15
Authors:
Moye, LA
Citation: La. Moye, End-point interpretation in clinical trials: The case for discipline, CONTR CL TR, 20(1), 1999, pp. 40-49
Authors:
Moye, LA
Annegers, JF
Citation: La. Moye et Jf. Annegers, Appetite-suppressant drugs and valvular heart disease, N ENG J MED, 340(6), 1999, pp. 477-477
Authors:
Plehn, JF
Davis, BR
Sacks, FM
Rouleau, JL
Pfeffer, MA
Bernstein, V
Cuddy, TE
Moye, LA
Piller, LB
Rutherford, J
Simpson, LM
Braunwald, E
Citation: Jf. Plehn et al., Reduction of stroke incidence after myocardial infarction with pravastatin- The cholesterol and recurrent events (CARE) study, CIRCULATION, 99(2), 1999, pp. 216-223
Authors:
Sacks, FM
Pfeffer, MA
Braunwald, E
Goldberg, RB
Mellies, MJ
Moye, LA
Davis, BR
Howard, BV
Howard, WJ
Cole, TG
Citation: Fm. Sacks et al., Baseline cholesterol level and magnitude of coronary event reduction in diabetic patients with myocardial infarction - Response, CIRCULATION, 100(25), 1999, pp. E154-E154
Authors:
Goldberg, RB
Mellies, MJ
Sacks, FM
Moye, LA
Howard, BV
Howard, WJ
Davis, BR
Cole, TG
Pfeffer, MA
Braunwald, E
Citation: Rb. Goldberg et al., Cardiovascular events and their reduction with pravastatin in diabetic andglucose-intolerant myocardial infarction survivors with average cholesterol levels - Subgroup analyses in the cholesterol and recurrent events (CARE)trial, CIRCULATION, 98(23), 1998, pp. 2513-2519
Risultati:
1-22
|